Induction of the transactivation function of p53 after cellular irradiation was studied under conditions in which upstream signaling events modulating p53 activation were uncoupled from those regulating stabilization. This investigation prompted the discovery of a novel radiation-responsive kinase pathway targeting Ser20 that results in the masking of the DO-1 epitope in undamaged cells. Unmasking of the DO-1 epitope via dephosphorylation occurs in response to low doses of nonionizing radiation. Our data show that phosphorylation at Ser20 reduces binding of the mdm2 protein, suggesting that a function of the Ser20-kinase pathway may be to produce a stable pool of inactive p53 in undamaged cells which can be readily activated after cellular injury. Phospho-speci®c monoclonal antibodies were used to determine whether the Ser20 signaling pathway is coupled to the Ser15 and Ser392 radiation-responsive kinase pathways. These results demonstrated that: (1) dephosphorylation at Ser20 is co-ordinated with an increased steady-state phosphorylation at Ser392 after irradiation, without p53 protein stabilization, and (2) stabilization of p53 protein can occur without Ser15 phosphorylation at higher doses of radiation. These data show that the Ser20 and Ser392 phosphorylation sites are both targeted by an integrated network of signaling pathways which is acutely sensitive to radiation injury.
Introduction
The tumor suppressor function of p53 protein is linked to its activity as a stress-responsive transcription factor. Cellular stresses that activate the sequence-speci®c transcription function of p53 protein include: ionizing and non-ionizing irradiation, ribonucleotide depletion, hypoxia, dierentiation signals, heat shock, low pH stress, and chemotherapeutic drugs (Oren and Prives, 1996) . Although a relatively comprehensive picture is being formulated regarding the gene products induced by p53, the upstream factors that regulate activation of p53 protein are only beginning to be de®ned. Previous models describing the mechanisms of stress-activated induction of p53 have been based on general observations that p53 protein can be either: (i) stabilized and activated by cell damage (Kastan et al., 1991; Lu and Lane, 1993) ; (ii) activated by irradiation in the absence of p53 protein stabilization ; or (iii) activated despite concomitant decreases in p53 protein levels (Lutzker and Levine, 1996) . The mechanisms involved depend, at least in part, upon the cell type and each model provides a distinct system to identify regulatory factors that can aect the p53 pathway.
More detailed biochemical studies have recently shown that cellular irradiation induces changes in the steady-state phosphorylation at three key regulatory sites in the amino and carboxy-terminal domains of p53 that may alter the speci®c activity of p53 as a transcription factor. Furthermore, such modulation of the speci®c activity of p53 by covalent modi®cation is likely to play a role in regulating its ability to suppress cancer formation and/or progression in vivo, as a recent study has shown that the tumor incidence rates are acutely in¯uenced by p53 gene dosage (Venkatachalam et al., 1998) . One of the most well-characterized in vitro regulatory motifs in human p53 resides at the Cterminal Casein Kinase 2-site (CK2; Ser392) whose phosphorylation can activate the latent sequencespeci®c DNA binding function of p53 Sakaguchi et al., 1997) , presumably by neutralizing the C-terminal negative regulatory domain. Cellular irradiation has been shown to trigger Ser392-site phosphorylation without p53 protein stabilization, even in the presence of the CK2 inhibitor, DRB (Blaydes and Hupp, 1998) . In addition, dephosphorylation of p53 at a second C-terminal site, within the PAb421 epitope, occurs after irradiation in an ATMdependent manner and may stimulate the binding of 14-3-3 proteins to the C-terminus of p53 (Waterman et al., 1998) . Together, these studies support previous microinjection data suggesting that modi®cation of the C-terminus of p53 may be one rate-limiting step in the activation of p53-dependent gene transcription and highlights the importance of identifying cellular enzymes that modify this regulatory domain of p53.
A second key regulatory step that controls p53 function involves the modulation of p53 turnover by the mdm2 ubiquitin-dependent degradation pathway (Haupt et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997) . The ability of monoclonal antibodies or peptides that target mdm2 protein to activate p53-dependent gene expression (Blaydes et al., 1997; Bottger et al., 1997) highlights the importance of identifying the cellular enzymes that modulate the rate of mdm2-p53 protein complex formation. Phosphorylation of p53 near the mdm2 binding interface by DNA-Dependent Protein Kinase (DNA-PK) can reduce mdm2 binding to p53 (Shieh et al., 1997; Siliciano et al., 1997) and identi®es the ®rst such cellular factor that can directly modify p53 and aect protein-protein complex formation with mdm2. In addition, Ser15 phosphorylation stimulates CBP/p300 binding to and acetylation of p53 (Lambert et al., 1998) , suggesting that the Ser15 kinase pathway can simultaneously reduce mdm2-dependent degradation of p53 protein and promote interaction of p53 with components of the transcriptional machinery. Whether all these signaling pathways function in the same cell type, whether they are damage-speci®c and whether their activation depends upon the threshold levels of damage has not been addressed.
Reported here is an integrated analysis of radiationdependent signaling to p53 protein at key amino-and carboxy-terminal regulatory sites to determine whether signaling cassettes targeting dierent domains of p53 are co-ordinately activated at dierent doses of a damaging agent. We report that: (1) the most ubiquitous damage-activated pathway targets the Cterminal Ser392-site and forms a very sensitive probe for radiation injury; (2) Ser15 phosphorylation is not detected when p53 protein is stabilized by high doses of radiation, thereby identifying a stabilization pathway that is independent of phosphorylation at Ser15; and (3) masking of the DO-1 epitope by phosphorylation at Ser20 in proliferating cells and its dephosphorylation after irradiation identi®es a novel signaling pathway targeting the Ser20 site of human p53.
Results
Low levels of UV irradiation can unmask both the C-terminal PAb421 and N-terminal DO-1 epitopes Identifying the upstream signaling pathways that modulate the activation of p53 protein has been facilitated by developing a cell model in which low levels of radiation can activate p53-dependent gene expression without p53 protein stabilization. Using this cell line, our initial analysis of upstream signaling to p53 protein has shown that p53 activation correlates with an increased steady-state Ser392-site phosphorylation via a DRB-resistant pathway (Blaydes and Hupp, 1998) . To begin to identify other key radiationresponsive phosphorylation events, changes in Cterminal PAb421 epitope expression were ®rst examined, as PAb421 epitope masking re¯ects the phosphorylation status of the C-terminal PKC site (Hupp and Lane, 1994; Waterman et al., 1998) protein levels remain constant after activation of p53 function. Irradiation unmasks the PAb421 epitope ( Figure 2) suggesting that, in addition to the radiation-activated Ser392-site kinase pathway (Blaydes and Hupp, 1998) , a second radiationresponsive pathway operates that results in de- Figure 1 Quantitation of p53-dependent transcription after irradiation of A375 cells. A375 cells containing a stably integrated b-galactosidase reporter construct under control of p53 were described previously (Blaydes and Hupp, 1998) . The cells were exposed to the indicated doses of UV radiation (from 2 to 20 J/m 2 ) and were harvested 9 h after irradiation. The total bgalactosidase activity was quanti®ed from cell lysates and after the enzyme reactions were stopped, the absorbance was read at 405 nm. The relative b-galactosidase activity is plotted as Absorbance at 405 nm vs increasing levels of irradiation Figure 2 Unmasking of the DO-1 and PAb421 epitopes of human p53 after irradiation of A375 cells. Proliferating A375 cells were exposed to a UV radiation source at 10 J/m 2 and 9 h after damage, cells were harvested in PBS and frozen. Lysates were prepared as indicated in the Materials and methods. Immunoreactive p53 protein captured from the lysates by the monoclonal antibodies was detected with p53-speci®c polyclonal anti-serum from rabbit and quantitated using peroxidase conjugated secondary anti-rabbit IgG with TMB by absorbance at 450 nM using a Dynatech MRX1 ELISA plate reader. The data are plotted as the amount of p53 protein captured (Absorbance at 450 nm) with the indicated monoclonal antibody before irradiation (closed bar) or after irradiation (stippled bar) phosphorylation at the PAb421 epitope (see also Waterman et al., 1998) . The monoclonal antibody DO-1 was also used in the ELISA, initially as a control because DO-1 is typically used to quantify absolute p53 protein levels and it was expected to give rise to data similar to that obtained with PAb1620. Surprisingly, however, a signi®cant unmasking of the DO-1 epitope occurred after irradiation (Figure 2) , suggesting the existence of a previously unreported site of posttranslational modi®cation within the DO-1 epitope.
Phosphorylation at Ser20 in the BOX-I domain masks the DO-1 epitope
The types of post-translational modi®cations that could be masking the antibody DO-1 binding to its epitope in proliferating cells may be important to de®ne, as the mdm2 binding site (amino acids 19 ± 26) is contained within the monoclonal antibody epitope DO-1 (amino acids 20 ± 25). To determine whether the predominant modi®cation is phosphorylation, A375 lysates from undamaged cells were incubated with a lysate enriched for okadaic acid-sensitive protein phosphatases and assayed for changes in DO-1 epitope exposure ( underestimates the basal phosphorylation within the DO-1 epitope in proliferating cells, as the dialysis of A375 lysates to remove phosphatase inhibitors actually increases the basal DO-1 epitope expression of p53 through the action of endogenous phosphatases in the lysate (data not shown). Nearly complete masking of the DO-1 epitope can only be detected when lysates from proliferating cells are prepared in denaturing buers that minimise de-phosphorylation during lysis (see Figure 6b and Figure 7) .
Having determined that DO-1 epitope masking was due to phosphorylation, a quantitative phosphopeptide-binding ELISA was subsequently developed to determine which phosphorylation site could alter the anity of DO-1 for its binding site. Potential sites that could aect DO-1 binding include: (i) the DNA-PK site at Ser15; (ii) a potential phosphorylation site at Thr18; and (iii) another potential phosphorylation site at Ser20. A series of biotinylated phospho-peptides were synthesized and used to study changes in the relative anity of DO-1 binding to its epitope. The monoclonal antibody DO-1 bound with a similar anity to unphosphorylated peptides or peptides with phosphate at Ser15 (Figure 4a ) or Thr18 (data not shown), and only a phosphate at Ser20 inhibited DO-1 binding ( Figure 4a ). The sensitivity of DO-1 binding to a phospho-Ser20 peptide is consistent with the ®ne mapping speci®city of DO-1 binding to its epitope (Stephen et al., 1995) , in which the minimal DO-1 epitope identi®ed using phage-peptide display is Ser20-Asp21-Leu22-(x)-Lys24-Leu25. Phosphatase treatment of the phospho-Ser20 peptide restored DO-1 binding to its epitope (Figure 4a ), establishing that the synthetic peptide can bind DO-1 after dephosphorylation.
Studies were also carried out to determine whether the Ser20 phospho-peptide exhibited any dierential anity for mdm2 protein (Figure 4b ). Compared to the control, unphosphorylated peptide, mdm2 protein binding was increasingly reduced by phosphorylation at Ser20, Ser15, and Thr18, respectively. Although the Ser15, Thr18, and Ser20 amino acid side-chains do not make direct contacts at the core interface with mdm2, both the Thr18 and Asp21 side chains form hydrogen bonds that contribute to the initiation of p53 helical structure within the mdm2 binding cleft (Kussie et al., 1996) . Thus, disruption of the hydrogen bonds at amino acid position 18 by the substitution of phospho-Thr18 may explain why mdm2 binding is more potently inhibited than by the phospho-Ser15 or phospho-Ser20 substitutions. Together, these results localize the phosphorylation site most likely to be involved in blocking DO-1 binding to p53 protein (Ser20) and indicate that mdm2 protein and antibody DO-1 show overlapping but distinct speci®cities for phosphoepitopes in the conserved BOX-I domain of p53.
Low levels of irradiation unmask the N-terminal DO-1 epitope and stimulate Ser392 phosphorylation
To form a concerted picture of how the Ser20 signaling pathway is coupled to two known radiation-responsive kinase pathways which have a well-de®ned eect on the biochemical function of p53 (targeting Ser15 and Ser392), monoclonal antibodies speci®c for phosphoSer15 and phospho-Ser392 were used as probes to determine whether dephosphorylation at Ser20 corre- Figure 3 Phosphorylation masks the DO-1 epitope. Dialysed lysates (2.7 mg, prepared as indicated in the Materials and methods) from proliferating A375 cells containing predominantly DO-1 non-reactive p53 was incubated in 10 ml of Buer D (10% glycerol, 25 mM HEPES, pH 7.6, 50 mM NaCl, 5 mM MgCl 2 , 1 mM DTT, 0.02% Triton X-100, 1 mM benzamidine) at 378C for 1 h: alone (left lane); with 1 mg of BALB/C liver lysate enriched for protein phosphates (middle lane); and with 1 mg of BALB/C liver lysate containing 120 nM okadaic acid (right lane). The reaction products were immunoblotted after SDS-gel electrophoresis, processed by probing the blots with monoclonal antibody DO-1, and the histogram showing the relative band intensities was determined using a Sharp JX-330 Densitometer and Imagemaster software (Pharmacia). The arrow indicates the position of p53 protein lated with increased phosphorylation at Ser392 and/or Ser15 after irradiation. In addition, we also examined whether dephosphorylation at Ser20 correlated with p53 protein stabilization. Denaturing immunoblots of lysates were used to quantitate changes in the phosphorylation status of p53 protein using a panel of phospho-sensitive, phospho-insensitive, and phospho-speci®c monoclonal antibodies that bind to p53 protein. The antibodies include: DO-12 (speci®c for the core domain and allows absolute quantitation of denatured p53 protein levels by immunoblotting); DO-1 (speci®c for the BOX-I domain, [which is sensitive to Ser20 phosphorylation]); FP3 (speci®c for CK2-site phosphorylated p53 at Ser392); and FPS15 (speci®c for phospho-Ser15, see below).
Using low levels of radiation (10 J/m 2 ) which give half-maximal induction of p53 activity (see Figure 1) , immunoblotting demonstrates that there are no increases in p53 protein levels using the antibody DO-12 ( Figure 5 , left lane vs middle lane). These data are consistent with a previous report using A375 cells demonstrating that p53 transactivation function is activated by low doses of irradiation without an increase in p53 protein levels (Blaydes and Hupp, 1998) and arms the use of PAb1620 in the ELISA to quantitate absolute levels of native p53 protein (see Figure 2) . Similar to that quantitated using the ELISA (Figure  2) , a striking unmasking of the DO-1 epitope (Figure 5 , left lane vs middle lane) occurred at low levels of irradiation under conditions in which p53 protein levels do not increase. Additionally, a low level of irradiation promotes an increase in steady-state phosphorylation of p53 at the C-terminal Ser392-site without p53 protein stabilization (Figure 5 , left lane vs middle lane, using the phospho-Ser392 speci®c monoclonal antibody FP3) indicating that two distinct signaling pathways targeting Ser20 and Ser392 respond to low doses of radiation under conditions in which p53 protein is activated as a transcription factor. However, this cell line does not recruit the Ser15 kinase pathway as there is no detectable increase in FPS15 immunoreactivity following irradiation ( Figure 5 ).
Higher levels of UV irradiation (20 J/m 2 ) giving maximal p53-dependent gene expression (see Figure 1 ) resulted in a pronounced induction of p53 protein levels (DO-12 immunoreactive p53; Figure 5 , left lane vs right lane) and increased Ser392 phosphorylation Figure 4 DO-1 and mdm2 protein binding to BOX-I domain peptides is reduced by a phospho-Ser20 substitution. ELISA wells were coated with streptavidin at a concentration of 5 mg/ml and non-reactive sites were blocked with a PBS buer containing 3% BSA and 0.1% Tween-20. Synthetic biotinylated, unphosphorylated or phosphorylated peptides containing the core sequence Biotin-linker-(GGGG)-EPPLSQETFSDLWK with phosphate at either Ser15, Thr18, or Ser20, as indicated, were captured in the ELISA wells by incubating in a PBS buer containing 3% BSA, 0.1% Tween-20, 50 mM NaF, and 12 nM okadaic acid. Where indicated, ®xed amounts of (a) MAb DO-1 (25 ng) or (b) full length mdm2 protein (40 ng) were added to the respective ELISA wells for 1 h. In part A, a control was included which involved a prior incubation of the peptides with 0.06 U potato acid phosphatase to establish the phospho-Ser20 sensitivity of the DO-1 epitope. DO-1 antibody bound to the peptides was detected by incubating with HRP-conjugated anti-mouse IgG and mdm2 bound to the peptides was detected using the mdm2-speci®c monoclonal antibody (4B2) followed by HRP-conjugated antimouse IgG. The data is represented as O.D. (450 nM) using the TMB colorimetric peroxidase assay Together, these data: (1) identify a novel signaling pathway targeting the DO-1 epitope in proliferating cells that changes at low levels of irradiation; (2) con®rm the presence of a Ser392-site signaling pathway that is stimulated by low doses of irradiation; and (3) uncouple p53 protein stabilization from Ser15 phosphorylation.
Previous data has shown that Ser15 phosphorylation occurs in irradiated EBV-transformed lymphocytes or certain tumor cell lines (Siliciano et al., 1997; Shieh et al., 1997) , so the inability to detect Ser15 phosphorylation after irradiation of A375 cells was unexpected. However, there can be no doubt about the quality of the FPS15 reagent, as this monoclonal antibody has been well characterized and binds speci®cally to the phospho-Ser15 epitope with a high anity (Figure 6a ). Additionally, a signi®cant increase in FPS15 immunoreactivity is observed after exposure of cells from 5 to 25 mg/ml cisplatin, but not transplatin (Figure 6b Immunochemical evidence for extensive modi®cation of human p53 at the DO-1 epitope (Ser20) in human breast cancers
Masking of the DO-1 epitope via Ser20 phosphorylation in proliferating cells is not con®ned to A375 cells. p53 protein in proliferating, normal human diploid ®broblasts is also predominately modi®ed in the DO-1 epitope and a striking unmasking of the DO-1 epitope can occur following the damage induced by labeling cells with 35 S-methionine or 32 P-orthophosphate (Bond et al., 1999) . In addition, predominant masking of the DO-1 epitope was also detected in over 70% of a panel of primary breast cancers with wild-type p53 status (Figure 7) . Absolute p53 protein levels were de®ned for each biopsy using DO-12 (Figure 7 , top panel, lanes A ± W). In four of these 23 representative samples, p53 protein is predominantly DO-1-reactive and presumably unphosphorylated at the DO-1 epitope (Figure 7 , lanes D, E, F and J). The majority of cancers, however, expressed p53 protein that was predominantly masked at the DO-1 epitope (Figure 7, lanes C, G, I , K, L, N, O, S and T). In addition, the substantial immunoreactive species bound by DO-1 with a molecular weight larger than p53 protein indicates that the DO-1 antibody recognises a contaminant protein in breast cancer tissues and we postulate that this contaminating protein may give rise to false-positives during immunostaining of tissue sections. Nervertheless, these data show that DO-1 epitope masking occurs in vivo in a large panel of breast cancers and further indicates that DO-1 epitope masking is physiologically relevant and not speci®c to the A375 cell model.
Discussion
In analysing the mechanism of p53 activation by irradiation in a cell line where wild-type p53 protein levels are not induced, three ®ndings highlight the existence of distinct signaling pathways that respond to dierent doses and types of damaging agent. Firstly, the most sensitive damage-activated pathway targets the C-terminal Ser392-site, which can regulate sequence-speci®c DNA binding function of p53 in vitro. This pathway is stimulated by both low and high doses of UV ( Figure 5 ) and by ionizing radiation (unpublished data). The apparently common recruitment of the Ser392-site kinase pathway identi®es a phosphorylation site that is as reliable a probe for a b Figure 6 Signaling to the Ser15 phosphorylation-site in damaged cells. (a) Speci®city of monoclonal antibody FPS15 for the phospho-Ser15 epitope. Quantitative ELISA as described in the legend of Figure 4 demonstrates the speci®city of the FPS15 monoclonal antibody for the phospho-Ser15 epitope. Puri®ed FPS15 monoclonal antibody (10 ng) was added into ELISA wells precoated with the indicated synthetic peptides and antibody binding to synthetic peptides was quantitated as described in the legend of Figure 4 . (b) Phosphorylation of p53 at Ser15 after high doses of cisplatin treatment of A375 cells. A375 cells were exposed to the indicated amounts of transplatin or cisplatin (mg/ ml) and 9 h after treatment, the cells were harvested and lysates prepared for immunoblotting as indicated in the Materials and methods. The blots were probed with the indicated monoclonal antibodies, from the top: FPS15 (panel I); DO-1 (panel II); FP3 (panel III); and . The arrows mark the position of p53 protein cellular damage as the Ser15-kinase pathway, if not more so. Secondly, the Ser15-kinase cascade does not generally target p53 protein in this cell model, even after higher doses of irradiation where p53 protein is stabilized. These data identify a p53-stabilization pathway that is independent of phosphorylation at Ser15 and provide a cell model to study this Ser15-phosphorylation-independent stabilization mechanism. Finally, a novel kinase pathway targeting p53 protein in proliferating cells has been identi®ed by virtue of DO-1 monoclonal antibody epitope masking via phosphorylation at Ser20. The DO-1 epitope masking also predominates in breast cancers containing largely proliferating cell populations (Figure 7 ) and in normal human diploid ®broblasts (Bond et al., 1999) indicating that this pathway may be a common feature of many proliferating cell types.
It is important to note that the Ser20 phosphorylation site has not been mapped before on p53 using standard radioactive 32 P-orthophosphate labeling methods and we propose the following explanation to account for this. Although the study of phosphorylation primarily involves labeling cells with 32 P-orthophosphate followed by phospho-amino acid analysis or peptide sequencing of the protein of interest (van der Geer et al., 1993) , it is now evident that radioactive precursors ( 35 S-methionine and 3 H-thymidine) can activate p53-dependent growth arrest and stressresponsive signaling pathways (Yeargin and Hass, 1995; Dover et al., 1994) which will perturb the baseline phosphorylation of proteins involved in the damage response. More recent work has shown that the damage induced by radioactive 32 P-orthophosphate labeling methods normally used to map phosphorylation sites activates a p53-dependent growth arrest pathway in normal human diploid ®broblasts (Bond et al., 1999) . In addition, the cellular damage induced by these same methods results in unmasking of the DO-1 epitope without an increase in p53 protein levels (Bond et al., 1999) indicating that the damage induced by the act of 32 P labeling may preclude ecient labeling at Ser20.
Expression of the DO-1 epitope of p53 protein in primary breast cancer biopsies was analysed to determine whether Ser20 phosphorylation was widespread and also to begin to address p53 phosphorylation in vivo. Many breast cancers analysed showed a high degree of DO-1 epitope masking on p53 and all cancers were previously untreated so there can be no eects of chemotherapy or endocrine therapy on altering the modi®cation of the DO-1 epitope. This suggests that the DO-1 epitope masking via Ser20 phosphorylation is not a`damage' response but is induced by signals in proliferating cells. This hypothesis would be consistent with the data in cell lines (A375 and in normal human diploid ®broblasts) showing that DO-1 epitope masking (Ser20 phosphorylation) can occur in undamaged, proliferating cells. Apart from the possibility that the BOX-1 signaling pathway directly aects cancer growth, modi®cation at Ser20 may also give rise to false-negatives in immunohistochemistry (IHC); that is, DO-1 reactive p53 does not re¯ect absolute levels of p53 protein, but de®nes the amount of p53 protein that remains unphosphorylated at Ser20. For example, one study concluded that increased expression of p53 in breast cancers is associated with a poor prognosis, and that this may de®ne a group of patients with tumors unlikely to respond to hormonal therapy (Berns et al., 1998) . This study employed the monoclonal antibodies DO-1 and DO-7, which share an identical speci®city with regards to binding to the BOX-1 domain of p53 (Stephen et al., 1995) . It is possible that alterations in dephosphorylation at this epitope can occur during tissue manipulation ex vivo, resulting in variability in the apparent DO-1 reactive p53 protein levels.
The signi®cance of phosphorylation at Ser20 on human p53 in proliferating cells remains unclear, but two major hypotheses exist based on the two proteins whose binding to p53 is known to be aected by mutation in the BOX-I domain: mdm2 and RNA Polymerase III. Firstly, as Ser20 phosphorylation occurs predominantly in proliferating cells, it may reduce the rate of mdm2-dependent degradation of p53, permitting the existence of a stable pool of inactive p53 poised for post-translational activation after irradiation by changes in phosphorylation at Ser392 and the PAb421 epitope (Ser371/376/378). Whilst this work was under revision, a report was Figure 7 Masking of the DO-1 epitope of human p53 in a large panel of primary human breast cancers. A breast cancer archive with a de®ned status for p53 mutation and immunohistochemical staining for p53 protein (Thompson et al., 1998) was lysed in denaturing urea lysis buer as indicated for the cells in the Materials and methods and analysed by immunoblotting to determine the extent of DO-1 epitope masking. The representative blots include a series of 23 samples (lanes A ± W) in which absolute p53 protein levels are de®ned with DO-12 (top panel) and DO-1 immunoreactive levels are de®ned with the bottom panel. The arrow marks the migration of p53 protein published showing that mutation of Ser20 to an Alanine residue is associated with a reduction in p53 protein expression using transient transfection assays (Unger et al., 1999) . In the light of our studies, we would interpret these results to indicate that an inability to phosphorylate p53 at Ser20 in proliferating cells sensitizes p53 to degradation by the mdm2 pathway. Basal phosphorylation of p53 protein at Ser20 in undamaged cells may reduce the rate of mdm2-dependent degradation of p53 protein, yielding a stable pool of inactive p53 that can be activated posttranslationally after exposure to low levels of radiation without the need for p53 protein synthesis. Secondly, Ser20 phosphorylation in proliferating cells may reduce the binding of p53 to other proteins that target the BOX-I domain, and which are themselves key regulators of growth control. Mutation of amino acid residues in the mdm2 binding site of p53 can also reduce the binding of RNA Polymerase III to p53 (Chesnokov et al., 1996) . It is clear then that Ser20 phosphorylation in proliferating cells may reduce the rate of p53 binding to and inhibition of RNA Polymerase III, and thus permit ecient Pol IIIdependent gene transcription coupled to normal growth control (Cairns and White, 1998) .
In conclusion, the novel ®nding in this report that forms the core of the study was the masking of the DO-1 epitope via Ser20 phosphorylation of p53 protein that led us to identify a signaling pathway targeting the BOX-I domain of human p53 in proliferating cells. We further determined whether concerted changes at two additional key regulatory sites occur following cellular injury and we report: (1) the most ubiquitous damageactivated pathway targets the C-terminal Ser392-site and forms a very sensitive probe for radiation injury; (2) Ser15 phosphorylation was not detected when p53 protein was stabilized by high doses of radiation, identifying a stabilization pathway that is independent of phosphorylation at Ser15; and (3) masking of the DO-1 epitope by phosphorylation at Ser20 in proliferating cells and its dephosphorylation after irradiation identi®es a novel signaling cassette targeting the Ser20 site of human p53 that may play a role in modulating the rate of mdm2-dependent degradation of p53 and the regulation of PolIII-dependent gene expression. Future research is being geared towards developing cell-free assays for the Ser20 kinase and phosphatases based on cells that express these pathways in order to study their function and regulation.
Materials and methods
Enzymes, cells, and reagents A375 cells were described previously (Blaydes and Hupp, 1998) and were grown in DMEM medium containing 10% fetal calf serum. The epitopes for the monoclonal antibodies DO-1, DO-12, PAb421, and PAb1620 have been described previously (Stephen et al., 1995; Vojtesek et al., 1995; Ravera et al., 1998) . Phospho-peptides were synthesized and puri®ed by Dr Graham Bloomberg, University of Bristol. A phosphopeptide from the N-terminal BOX-I domain of human p53 with a phosphate at Ser15 (amino acids 13 ± 27 (Soussi and May (1996) ) was used to generate the monoclonal antibody FPS15, whose speci®city for the phospho-Ser15 epitope is shown by ELISA in Figure 6a . A phospho-peptide from the C-terminal Ser392-site of human p53 with a phosphate at Ser392 (amino acids 379 ± 393 (Soussi and May (1996) ) was used to generate the monoclonal antibody FP3, whose speci®city for the phospho-Ser392 epitope is similar to the polyclonal antibody to the phospho-Ser392 site we have described previously (Blaydes and Hupp, 1998) . Biotinylated peptides and phospho-peptides from amino acids 13 ± 27 of human p53 were obtained from Chiron Mimotopes. Streptavidin and Potato acid phosphatase were obtained from Sigma. Full length Mdm2 protein was partially puri®ed following expression in a T7.7/E. Coli expression system (unpublished methods). The UV-c radiation source was a Stratagene 2400 crosslinker. A cell line derived from A375 cells containing a stably transfected p53-dependent bgalactosidase reporter construct (Arn.8) was used to analyse p53-dependent transcription, and the colorimetric analysis of total b-galactosidase activity in cell lysates was determined as described previously (Blaydes and Hupp, 1998) . p53 protein captured by two-site ELISA was quantitated as indicated previously .
Whole cell lysates from A375 cells were prepared by adding Detergent Lysis Buer (1% IGEPAL; 50 mM HEPES (pH 7.6); 5 mM DTT; 0.4 M KCl; 1 mM benzamidine, and including 50 mM NaF, and 120 nM okadaic acid to preserve phospho-epitopes) to cell pellets and incubating on ice for 15 min. Following centrifugation at 10000 g for 10 min at 48C, the extracted protein was quantitated using the method of Bradford (1976) . Denaturing lysis was used to ensure preservation of phospho-epitopes during lysis and was performed as above, but in a buer containing: 8 M Urea; 50 mM HEPES (pH 7.6); 5 mM DTT; 0.4 M KCl; 1 mM benzamidine, 50 mM NaF, and 120 nM okadaic acid. To allow phosphatase treatment of A375 detergent extracts, phosphatase inhibitors were removed by incubating 100 ml of lysate in buer O (15% glycerol, 25 mM HEPES (pH 7.6), 1 mM DTT, 0.1% tween-20, 1 mM benzamidine, and 0.2 M KCl) and dialysing for 4 h in a cold room using Spectropor dialysis tubing (12 000 ± 14 000 molecular weight cut-o) with three buer changes. Dialysed lysates containing p53 protein were added to 10 ml of buer L (15% glycerol, 25 mM HEPES (pH 7.6), 1 mM MgCl 2 , 1 mM DTT, 0.1% tween-20, 3% BSA, 1 mM benzamidine, and 0.2 M KCl), and a BALB/c murine liver lysate fraction containing okadaic acidsensitive protein phosphatases and incubated at 308C for 30 min before immunoblotting.
